His studies link Cognitive decline with Disease. With his scientific publications, his incorporates both Alzheimer's disease and Episodic memory. Borrowing concepts from Cognition, Christopher C. Rowe weaves in ideas under Episodic memory. He carries out multidisciplinary research, doing studies in Cognition and Neuropsychology. He undertakes multidisciplinary investigations into Neuropsychology and Dementia in his work. Christopher C. Rowe carries out multidisciplinary research, doing studies in Dementia and Frontotemporal dementia. Pathology connects with themes related to Amyloid (mycology) in his study. His study ties his expertise on Pathology together with the subject of Amyloid (mycology). In his study, Christopher C. Rowe carries out multidisciplinary Internal medicine and Oncology research.
Cognitive decline and Pittsburgh compound B are the two main areas of interest in his Dementia studies. He is exploring Cognition as part of his Episodic memory, Cognitive impairment and Neuropsychology and Cognition studies. Christopher C. Rowe performs multidisciplinary study in the fields of Episodic memory and Alzheimer's disease via his papers. In his articles, Christopher C. Rowe combines various disciplines, including Alzheimer's disease and Pittsburgh compound B. As part of his studies on Cognitive impairment, he often connects relevant areas like Disease. His Disease study frequently links to adjacent areas such as Cognitive decline. In his works, Christopher C. Rowe performs multidisciplinary study on Neuropsychology and Dementia. In the field of Neuroimaging Christopher C. Rowe connects related research areas like Neuroscience and Psychiatry. He undertakes multidisciplinary studies into Neuroscience and Cognition in his work.
By researching both Internal medicine and Endocrinology, Christopher C. Rowe produces research that crosses academic boundaries. He connects Endocrinology with Internal medicine in his research. Christopher C. Rowe regularly ties together related areas like Neurodegeneration in his Disease studies. His work on Disease expands to the thematically related Neurodegeneration. His study on Dementia is mostly dedicated to connecting different topics, such as Cognitive decline. Cognitive decline connects with themes related to Dementia in his study. With his scientific publications, his incorporates both Nuclear medicine and Positron emission tomography. Christopher C. Rowe integrates many fields in his works, including Positron emission tomography and Radiology. Christopher C. Rowe undertakes interdisciplinary study in the fields of Radiology and Nuclear medicine through his works.
His Cohort study research includes a combination of various areas of study, such as Prospective cohort study and Cohort. He connects Cohort with Cohort study in his research. His research combines Prospective cohort study and Internal medicine. His study connects Cognitive decline and Disease. His Cognitive decline study frequently draws connections between related disciplines such as Dementia. In his works, he performs multidisciplinary study on Dementia and Cognition. He integrates Cognition and Alzheimer's disease in his studies. By researching both Alzheimer's disease and Biomarker, he produces research that crosses academic boundaries. Many of his studies on Biomarker involve topics that are commonly interrelated, such as Biochemistry.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling;Paul S. Aisen;Laurel A. Beckett;David A. Bennett.
Alzheimers & Dementia (2011)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack;David A. Bennett;Kaj Blennow;Maria C. Carrillo.
Alzheimers & Dementia (2018)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L. Villemagne;Samantha Burnham;Pierrick Bourgeat;Belinda M. Brown.
Lancet Neurology (2013)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens.
Alzheimers & Dementia (2016)
Imaging beta-amyloid burden in aging and dementia.
Christopher C Rowe;Steven Ng;Uwe Ackermann;Sylvia Gong.
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Christopher C Rowe;Kathryn A Ellis;Kathryn A Ellis;Miroslava Rimajova;Pierrick Bourgeat.
Neurobiology of Aging (2010)
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura;Naoki Kaneko;Victor L Villemagne;Takashi Kato.
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
Kerryn Elizabeth Pike;Gregory Raymond Savage;Victor L Villemagne;Steven Ng.
Longitudinal Assessment of Aβ and Cognition in Aging and Alzheimer Disease
Victor L Villemagne;Kerryn E Pike;Gaël Chételat;Kathryn A Ellis.
Annals of Neurology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: